Table III.
Concentration of sphingolipids in: plasma, erythrocytes (RBC) and platelets (PLT): ovarian cancer patients and healthy women (control group)
| Sphingolipids | Concentration of sphingolipids in plasma (ng/100 ml) – median (25th –75th percentile) | RBC sphingolipid concentration (ng/100 ml) – median (25th –75th percentile) | PLT sphingolipid concentration (ng/ml) – median (25th –75th percentile) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Ovarian cancer patient (n = 135) | Control group (n = 159) | P-value | Ovarian cancer patient (n = 135) | Control group (n = 159) | P-value | Ovarian cancer patient (n = 135) | Control group (n = 159) | P-value | |
| Total Cer | 4236.40 (2276.54–6874.37) | 3772.72 (2976.38–5743.34) | 0.244 | 100.15 (69.41–123.89) | 101.42 (76.56–114.38) | 0.642 | 444.13 (314.60–570.14) | 382.67 (259.09–523.81) | 0.499 |
| SPH | 77.84 (33.39–91.29) | 96.74 (47.98–156.34) | 0.201 | 1.00 (0.49–1.29) | 0.97 (0.46–1.14) | 0.573 | 127.08 (47.33–203.12) | 145.18 (43.24–141.49) | 0.978 |
| SPA | 27.56 (9.26–46.77) | 26.87 (8.90–44.80) | 0.843 | 0.18 (0.09–0.21) | 0.17 (0.12–0.21) | 0.583 | 24.75 (10.21–43.93) | 31.87 (10.84–36.96) | 0.757 |
| S1P | 424.63 (271.84–601.40) | 420.35 (301.39–590.35) | 0.844 | 18.08 (10.49–23.31) | 14.44 (9.48–19.44) | 0.083 | 244.38 (127.57–292.28) | 234.34 (100.10–340.13) | 0.714 |
| C14:0-Cer | 7.70 (3.94–12.13) | 8.09 (4.00–13.20) | 0.675 | 0.09 (0.07–0.11) | 0.09 (0.07–0.11) | 0.583 | 1.38 (0.69–1.62) | 1.34 (0.74–1.53) | 0.704 |
| C16:0-Cer | 403.67 (261.39–660.28) | 261.60 (119.90–387.40) | 0.021* | 8.93 (6.73–11.55) | 8.26 (6.84–9.48) | 0.481 | 73.96 (51.07–97.67) | 68.37 (46.71–87.79) | 0.583 |
| C18:1-Cer | 7.35 (4.00–13.00) | 3.89 (1.02–7.25) | 0.036* | 0.10 (0.08–0.22) | 0.08 (0.0439–0.0918) | 0.027* | 1.06 (0.65–1.19) | 0.98 (0.65–1.25) | 0.642 |
| C18:0-Cer | 161.74 (87.98–276.99) | 92.43 (54.57–159.34) | 0.031* | 2.78 (1.98–3.51) | 2.61 (1.97–3.46) | 0.833 | 38.36 (20.82–50.82) | 30.66 (16.55–43.13) | 0.226 |
| C20:0-Cer | 117.20 (46.86–181.74) | 104.85 (55.33–176.55) | 0.056 | 1.53 (1.02–1.82) | 1.65 (1.19–1.98) | 0.360 | 61.35 (33.98–72.64) | 48.52 (33.08–58.87) | 0.304 |
| C22:0-Cer | 557.78 (221.62–723.72) | 514.97 (200.29–754.87) | 0.444 | 9.77 (6.66–11.58) | 11.39 (6.26–14.28) | 0.704 | 95.44 (63.02–130.85) | 88.14 (54.20–107.78) | 0.989 |
| C24:1-Cer | 1332.82 (501.28–1991.82) | 1174.83 (499.11–1799.37) | 0.073 | 49.89 (34.02-52.25) | 43.53 (34.26–52.26) | 0.237 | 95.23 (64.02–109.61) | 70.31 (44.84–86.38) | 0.067 |
| C24:0-Cer | 1648.14 (520.38–2288.77) | 1470.15 (512.00–2234.66) | 0.421 | 27.06 (12.97-37.33) | 33.83 (12.79–36.54) | 0.989 | 77.34 (53.71–85.49) | 74.37 (46.48–95.75) | 0.767 |
*
Statistically significant value of less than 0.05 for Mann-Whitney test.
CER – ceramides, Sph – sphingosine, SPA – sphinganine, S1P – sphingosine-1-phosphate, C14:0-Cer – ceramides containing myristic acid, C16:0-Cer – ceramides containing palmitic acid, C18:1-Cer – ceramides containing oleic acid, C18:0-Cer – ceramides containing stearic acid, C20:0-Cer – ceramides containing arachidic acid, C22:0-Cer – ceramides containing behenic acid, C24:1-Cer – ceramides containing nervonic acid, C24:0-Cer – ceramides containing lignoceric acid.